1. Exploring the Mechanisms Underlying Cellular Uptake and Activation of Dendritic Cells by the GK-1 Peptide.
- Author
-
Cervantes-Torres J, Hernández-Aceves JA, Gajón Martínez JA, Moctezuma-Rocha D, Vázquez Ramírez R, Sifontes-Rodríguez S, Ramírez-Salinas GL, Mendoza Sierra L, Alfonzo LB, Sciutto E, and Fragoso G
- Abstract
The use of peptides for cancer immunotherapy is a promising and emerging approach that is being intensively explored worldwide. One such peptide, GK-1, has been shown to delay the growth of triple-negative breast tumors in mice, reduce their metastatic capacity, and reverse the intratumor immunosuppression that characterizes this model. Herein, it is demonstrated that GK-1 is taken up by bone marrow dendritic cells in a dose-dependent manner 15 min after exposure, more efficiently at 37 °C than at 4 °C, implying an entrance into the cells by energy-independent and -dependent processes through clathrin-mediated endocytosis. Theoretical predictions support the binding of GK-1 to the hydrophobic pocket of MD2, preventing it from bridging TLR4, thereby promoting receptor dimerization and cell activation. GK-1 can effectively activate cells via a TLR4-dependent pathway based on in vitro studies using HEK293 and HEK293-TLR4-MD2 cells and in vivo using C3H/HeJ mice (hyporesponsive to LPS). In conclusion, GK-1 enters the cells by passive diffusion and by activation of the transmembrane Toll-like receptor 4 triggering cell activation, which could be involved in the GK-1 antitumor properties., Competing Interests: The authors declare no competing financial interest., (© 2024 The Authors. Published by American Chemical Society.)
- Published
- 2024
- Full Text
- View/download PDF